查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591850

组蛋白去乙酰化酶抑制剂市场：按类别、应用分类 - 2025-2030 年全球预测

Histone Deacetylase Inhibitors Market by Class (Class I HDACs, Class II HDACs, Class III HDACs), Application (Central Nervous System Disorders, Neurology, Oncology) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年组蛋白去乙酰化酶抑制剂市值为164.3亿美元，预计2024年将达到183.2亿美元，复合年增长率为11.96%，到2030年将达到362亿美元，预计将达到5,000万美元。

组蛋白去乙酰化酶抑制剂（HDAC 抑制剂）是一类抑制组蛋白去乙酰化酶功能的化合物，组蛋白去乙酰化酶是一种参与修饰染色质结构和控制基因表现的酵素。 HDAC 抑制剂的主要用途是在肿瘤学中，利用其诱导癌细胞凋亡和细胞週期停滞的能力。然而，由于其在表观遗传调控中的作用，其应用范围也扩展到神经和发炎疾病。一系列最终用途包括主要专注于新型癌症治疗的製药公司，以及寻求阿兹海默症和亨廷顿治疗方法的研究人员。 HDAC 抑制剂市场的成长主要受到癌症和神经退化性疾病盛行率不断上升以及标靶治疗研发投资不断增加的影响。此外，生物资讯学和基因组学的技术进步透过实现更精确的药物设计而增加了市场潜力。目前的机会在于扩大 FDA核准的现有 HDAC 抑制剂治疗多发性骨髓瘤和其他癌症的适应症，以及探索与免疫肿瘤治疗的联合治疗。抗药性、副作用和表观遗传调控的复杂性等挑战，以及与临床测试相关的高昂成本和时间表，构成了重大障碍。我们相信，技术创新的最佳方向是提高 HDAC 抑制剂的选择性和治疗指数，开发用于患者分层的生物标誌物，并整合人工智慧来优化药物发现过程。 HDAC 抑制剂市场的竞争是温和的，许多小型生物技术公司和大型製药公司都希望取得进步，并且寻求扩大其产品组合和能力的公司有明显的整合和联盟趋势。公司可能会发现策略联盟的价值，以加速开发并引入有前途的先导化合物，以在这个充满活力的领域中保持竞争力。

主要市场统计
基准年[2023] 164.3亿美元
预测年份 [2024] 183.2亿美元
预测年份 [2030] 362.5亿美元
复合年增长率（%） 11.96%

市场动态：揭示快速发展的组蛋白去乙酰化酶抑制剂市场的关键市场洞察

供需的动态交互作用正在改变组蛋白去乙酰化酶抑制剂市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 癌症发生率增加，需要有效的治疗方法
    • 在慢性病的预后、治疗和诊断的应用不断增加
    • 由于其稳定情绪和抗癫痫的特性，精神病学和神经科。
  • 市场限制因素
    • 人才意识淡薄，报销政策缺失
    • 原料高成本且缺乏训练有素的专业人员
  • 市场机会
    • 采用先进技术并加强製造商和公司之间的合作
    • 政府和私人组织增加对药物开发的投资
  • 市场问题
    • 关于製造和潜在副作用（例如毒性）的严格规定

波特五力：驾驭组蛋白去乙酰化酶抑制剂市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解对组蛋白去乙酰化酶抑制剂市场的外部影响

外部宏观环境因素在塑造组蛋白去乙酰化酶抑制剂市场的绩效动态发挥关键作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解组蛋白去乙酰化酶抑制剂市场的竞争格局

对组蛋白去乙酰化酶抑制剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵：组蛋白去乙酰化酶抑制剂市场供应商的绩效评估

FPNV定位矩阵是评估组蛋白去乙酰化酶抑制剂市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製组蛋白去乙酰化酶抑制剂市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对组蛋白去乙酰化酶抑制剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症发生率增加以及有效治疗方法的需求
      • 在慢性病的预后、治疗和诊断的应用不断增加
      • 由于其稳定情绪和抗癫痫的特性，精神病学和神经科的需求正在增加。
    • 抑制因素
      • 人力资源意识缺乏，薪酬政策缺失
      • 原料高成本且缺乏训练有素的专业人员
    • 机会
      • 引进先进技术并扩大製造商和公司之间的合作
      • 政府和私人组织增加对药物开发的投资
    • 任务
      • 关于製造和潜在副作用（例如毒性）的严格规定
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章组蛋白去乙酰化酶抑制剂市场：依类别

  • 介绍
  • I 类 HDAC
  • Ⅱ 类 HDAC
  • III 类 HDAC

第七章组蛋白去乙酰化酶抑制剂市场：依应用分类

  • 介绍
  • 中枢神经系统疾病
  • 神经病学
  • 肿瘤学

第八章北美和南美组蛋白去乙酰化酶抑制剂市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太组蛋白去乙酰化酶抑制剂市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲组蛋白去乙酰化酶抑制剂市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AstraZeneca PLC
  • Bristol Myers Squibb Company
  • Celleron Therapeutics Ltd.
  • Eisai Co., Ltd.
  • Karyopharm Therapeutics Inc.
  • MEI Pharma Inc.
  • Merck KGaA
  • Midatech Pharma PLC
  • Novartis AG
  • Oncolys BioPharma Inc.
  • Regenacy Pharmaceuticals, Inc.
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Spectrum Pharmaceuticals, Inc.
  • Syndax Pharmaceuticals, Inc.
  • Tokyo Chemical Industry Co. , Ltd.
Product Code: MRR-437E9896A56B

The Histone Deacetylase Inhibitors Market was valued at USD 16.43 billion in 2023, expected to reach USD 18.32 billion in 2024, and is projected to grow at a CAGR of 11.96%, to USD 36.25 billion by 2030.

Histone deacetylase inhibitors (HDAC inhibitors) are a class of compounds that interfere with the function of histone deacetylases, enzymes implicated in modifying chromatin structure and regulating gene expression. Their primary necessity lies in oncology, where they are leveraged for their ability to induce apoptosis and cell cycle arrest in cancer cells. However, their application scope extends to neurological and inflammatory disorders, given their role in epigenetic modulation. The end-use scope primarily includes pharmaceutical companies focusing on novel cancer therapies and researchers exploring therapeutics for Alzheimer's and Huntington's diseases. Market growth for HDAC inhibitors is primarily influenced by an increasing prevalence of cancer and neurodegenerative disorders, coupled with heightened investment in research and development of targeted therapies. Additionally, technological advancements in bioinformatics and genomics bolster market potential by enabling more precise drug design. Current opportunities lie in expanding labels for existing FDA-approved HDAC inhibitors to treat multiple myeloma and other cancers, as well as exploring combination therapies alongside immuno-oncology agents. Challenges such as drug resistance, adverse effects, and the intricate nature of epigenetic regulation present significant hurdles, alongside the daunting costs and timelines associated with clinical trials. Innovation might best be directed toward improving the selectivity and therapeutic index of HDAC inhibitors, developing biomarkers for patient stratification, and integrating AI for optimizing drug discovery processes. The nature of the HDAC inhibitor market is moderately competitive with numerous small biotech firms and larger pharmaceutical companies striving for advancements, and a trend toward consolidation and collaboration evident as entities seek to expand their portfolios and capabilities. Businesses may find value in strategic alliances for accelerated development and in-lisencing promising lead compounds to stay competitive in this dynamic field.

KEY MARKET STATISTICS
Base Year [2023] USD 16.43 billion
Estimated Year [2024] USD 18.32 billion
Forecast Year [2030] USD 36.25 billion
CAGR (%) 11.96%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Histone Deacetylase Inhibitors Market

The Histone Deacetylase Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidence of cancer coupled with need for effective treatment therapies
    • Increasing application in prognosis, treatment and diagnosis of chronic diseases
    • Rising need from psychiatry and neurology attributed to their mood stabilizing and anti-epileptic properties
  • Market Restraints
    • Dearth of awareness among people and lack of reimbursement policies
    • High cost of raw material and lack of trained professionals
  • Market Opportunities
    • Rising adoption of advanced technologies and collaboration among manufacturers and companies
    • Increasing investment for drug development from government and private organizations
  • Market Challenges
    • Strict mandates for the production and probable side effects such as toxicity

Porter's Five Forces: A Strategic Tool for Navigating the Histone Deacetylase Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Histone Deacetylase Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Histone Deacetylase Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Histone Deacetylase Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Histone Deacetylase Inhibitors Market

A detailed market share analysis in the Histone Deacetylase Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Histone Deacetylase Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Histone Deacetylase Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Histone Deacetylase Inhibitors Market

A strategic analysis of the Histone Deacetylase Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Histone Deacetylase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bristol Myers Squibb Company, Celleron Therapeutics Ltd., Eisai Co., Ltd., Karyopharm Therapeutics Inc., MEI Pharma Inc., Merck KGaA, Midatech Pharma PLC, Novartis AG, Oncolys BioPharma Inc., Regenacy Pharmaceuticals, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Spectrum Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., and Tokyo Chemical Industry Co. , Ltd..

Market Segmentation & Coverage

This research report categorizes the Histone Deacetylase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Class, market is studied across Class I HDACs, Class II HDACs, and Class III HDACs.
  • Based on Application, market is studied across Central Nervous System Disorders, Neurology, and Oncology.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of cancer coupled with need for effective treatment therapies
      • 5.1.1.2. Increasing application in prognosis, treatment and diagnosis of chronic diseases
      • 5.1.1.3. Rising need from psychiatry and neurology attributed to their mood stabilizing and anti-epileptic properties
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of awareness among people and lack of reimbursement policies
      • 5.1.2.2. High cost of raw material and lack of trained professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising adoption of advanced technologies and collaboration among manufacturers and companies
      • 5.1.3.2. Increasing investment for drug development from government and private organizations
    • 5.1.4. Challenges
      • 5.1.4.1. Strict mandates for the production and probable side effects such as toxicity
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Histone Deacetylase Inhibitors Market, by Class

  • 6.1. Introduction
  • 6.2. Class I HDACs
  • 6.3. Class II HDACs
  • 6.4. Class III HDACs

7. Histone Deacetylase Inhibitors Market, by Application

  • 7.1. Introduction
  • 7.2. Central Nervous System Disorders
  • 7.3. Neurology
  • 7.4. Oncology

8. Americas Histone Deacetylase Inhibitors Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Histone Deacetylase Inhibitors Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Histone Deacetylase Inhibitors Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Bristol Myers Squibb Company
  • 3. Celleron Therapeutics Ltd.
  • 4. Eisai Co., Ltd.
  • 5. Karyopharm Therapeutics Inc.
  • 6. MEI Pharma Inc.
  • 7. Merck KGaA
  • 8. Midatech Pharma PLC
  • 9. Novartis AG
  • 10. Oncolys BioPharma Inc.
  • 11. Regenacy Pharmaceuticals, Inc.
  • 12. Shenzhen Chipscreen Biosciences Co., Ltd.
  • 13. Spectrum Pharmaceuticals, Inc.
  • 14. Syndax Pharmaceuticals, Inc.
  • 15. Tokyo Chemical Industry Co. , Ltd.

LIST OF FIGURES

  • FIGURE 1. HISTONE DEACETYLASE INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. HISTONE DEACETYLASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. HISTONE DEACETYLASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HISTONE DEACETYLASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HISTONE DEACETYLASE INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I HDACS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II HDACS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III HDACS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. HISTONE DEACETYLASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. HISTONE DEACETYLASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023